Drugs for type 2 diabetes

Med Lett Drugs Ther. 2022 Nov 14;64(1663):177-184.
No abstract available

Keywords: Actoplus; Actos; Adlyxin; Amaryl; Bydureon; Byetta; Duetact; Farxiga; Glucotrol; Glumetza; Glynase; Glyxambi; Invokamet; Invokana; Janumet; Januvia; Jardiance; Jentadueto; Kazano; Kombiglyze; Mounjaro; Nesina; Onglyza; Oseni; Ozempic; Qtern; Riomet; Rybelsus; Saxenda; Segluromet; Soliqua; Steglatro; Steglujan; Synjardy; Tradjenta; Trulicity; Victoza; Wegovy; Xigduo; Xultophy; acarbose; adverse effects; alogliptin; canagliflozin; dapagliflozin; degludec; dosage; drug interactions; dulaglutide; efficacy; empagliflozin; ertugliflozin; exenatide; glargine; glimepiride; glipizide; glyburide; insulin; lactation; linagliptin; liraglutide; lixisenatide; metformin; miglitol; nateglinide; pioglitazone; pregnancy; repaglinide; rosiglitazone; safety; saxagliptin; semaglutide; sitagliptin; tirzepatide; type 2 diabetes.

MeSH terms

  • Antipsychotic Agents*
  • Diabetes Mellitus, Type 2* / diagnosis
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents / adverse effects

Substances

  • Hypoglycemic Agents
  • Antipsychotic Agents